Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 2/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 6/20 | 0.32 |
| ▸ | MAPT | P10636 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | VDR | P11473 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3783208 | 0.81 | PTGS1 (0.36) | PTGDR2SMN1; SMN2 | |
| SCHEMBL3778570 | 0.80 | ENPP2 (0.34) | ALDH1A1SMN1; SMN2HTT | |
| SCHEMBL3784962 | 0.77 | PPARD (0.44) | PTGDR2AKR1B1TP53MAPTVDR | |
| SCHEMBL3776832 | 0.74 | VDR (0.41) | PTGDR2TP53MAPTVDRPOLB | |
| SCHEMBL3778746 | 0.73 | TP53 (0.39) | TYMSDHFRPTGDR2AKR1B1TP53 | |
| SCHEMBL3782988 | 0.71 | MBOAT4 (0.35) | PTGDR2 | |
| SCHEMBL3788385 | 0.71 | PTGDR2 (0.43) | TYMSDHFRPTGDR2AKR1B1TP53 | |
| SCHEMBL3778397 | 0.69 | VDR (0.40) | TYMSDHFRPTGDR2AKR1B1TP53 | |
| SCHEMBL23166109 | 0.68 | EPAS1 (0.41) | TP53ALDH1A1 | |
| SCHEMBL3775986 | 0.68 | PPARD (0.39) | PTGDR2AKR1B1TP53MAPTVDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928457-B1 | QUINOLINES AND THEIR THERAPEUTIC USE | PULMAGEN THERAPEUTICS ASTHMA LTD (GB) | 2012-12-12 | — | — | EP | disclosed |
| US-7858640-B2 | Quinolines and their therapeutic use | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2010-12-28 | — | — | US | disclosed |
| US-20090156600-A1 | Quinolines and Their Therapeutic Use | GB005, INC. | 2009-06-18 | — | — | US | disclosed |
| EP-1928457-A2 | QUINOLINES AND THEIR THERAPEUTIC USE | Argenta Discovery Limited (GB) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007036743-A2 | QUINOLINES AND THEIR THERAPEUTIC USE | ARGENTA DISCOVERY LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156600-A1 | Quinolines and Their Therapeutic Use | NR3C1, NR3C2, NR1H3 | TYMS 3750/4885DHFR 1084/4885PTGDR2 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.